Donepezil Hydrochloride
FDA-approved product (tablet, oral), marketed as Adlarity, Aricept, Aricept Odt and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Alzheimer disease
- Dementia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Anticholinesterases
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis61.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Donepezil Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pipecuronium BromideExisting use: Other quaternary ammonium compounds42.9% AI-predicted activityagainst K. pneumoniae5 registered studies
- Fosaprepitant DimeglumineExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 3 more42.9% AI-predicted activityagainst K. pneumoniae21 registered studies
- CabergolineExisting use: Hypothalamic neoplasm, Parkinson disease42.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more42.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder42.6% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Vecuronium BromideExisting use: Other quaternary ammonium compounds42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease42.0% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia41.9% AI-predicted activityagainst K. pneumoniae6 registered studies
- RepotrectinibExisting use: Cancer, Neoplasm41.8% AI-predicted activityagainst K. pneumoniae17 registered studies
- MoxidectinExisting use: Helminthiasis, Onchocerciasis41.7% AI-predicted activityagainst K. pneumoniae25 registered studies
- PralsetinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 1 more41.5% AI-predicted activityagainst K. pneumoniae19 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
NCT00315367 · start 2004-09
Registered record
- Registry ID
- NCT00315367
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Donepezil HCI (drug)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-09
- Completion
- 2007-10
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRelapsing-Remitting Multiple SclerosisInterventionDonepezil HCI (drug)PhasePhase 4Registry statusCompletedAn Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis
NCT01146509 · start 2003-01
Registered record
- Registry ID
- NCT01146509
- Conditions
- Migraine Headache
- Interventions
- Aricept (donepezil hydrochloride)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-01
- Completion
- 2007-03
- Enrolment
- 89
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine HeadacheInterventionAricept (donepezil hydrochloride)PhasePhase 2Registry statusCompletedThe CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia
NCT00206947 · start 2002-12
Registered record
- Registry ID
- NCT00206947
- Conditions
- Schizophrenia
- Interventions
- donepezil (5-10 mg/day); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2002-12
- Completion
- 2005-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventiondonepezil (5-10 mg/day); PlaceboPhasePhase 2Registry statusTerminatedDonepezil to Treat Dementia in Parkinson's Disease
NCT00030979 · start 2002-02
Registered record
- Registry ID
- NCT00030979
- Conditions
- Parkinson Disease
- Interventions
- Donepezil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-02
- Completion
- 2005-03
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParkinson DiseaseInterventionDonepezilPhasePhase 4Registry statusCompletedTiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9
NCT00015132 · start 1999-03
Registered record
- Registry ID
- NCT00015132
- Conditions
- Cocaine-Related Disorders
- Interventions
- Sertraline
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1999-03
- Completion
- 2000-11
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCocaine-Related DisordersInterventionSertralinePhasePhase 2Registry statusCompleted